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 Abstract 
Introduction 
Atrial fibrillation (AF) is one of the series consequences of rheumatic 
valvular heart disease (RHD) which can occur early in the course or decade 
later. The prevalence of rheumatic AF is less in developed countries but 
data from developing countries showed that AF is the commonest 
arrhythmia and associated with stenotic valve abnormalities and dilated left 
atria. AF is associated with higher rate of complication such as, 
thromboembolism, decreased cardiac output (stroke volume), progression 
of left ventricular dysfunction and heart failure. This study examines the 
pattern, commonly associated valve abnormalities and list other associated 
factors with AF. 
Methods  
For this particular study, medical records of 136 patients age above 15 
years with rheumatic valvular heart disease(diagnosed by clinical and 
echocardiography) were retrieved. Documented atrial fibrillation (with EKG 
and/or clinically), a case-control retrospective observational study was 
made to evaluate the risk factros and predictors of AF in RHD patients. 
Results 
A total of 68 cases with equal proportion of control were assessed. The 
mean age (in year) was 27.4+/-9.3 and 26+/-10.9 in AF and no AF 
respectively. Female preponderance in both groups were 53(77.9%) in AF 
and 43(63.2%) in no AF was observed. the mean left atria (LA) dimensions 
are 57.7±12.8 (mm2) in AF and 43.9±9.1 (mm2) in no AF AOR (1.15(1.08-
1.22)) (P<0.0001). The duration of heart disease (years) was identified to be 
5.7±3.9 in AF and 3.9±2.9 in no AF groups AOR (1.23(1.01, 1.50)) (p<0.039).  
Conclusion 
Factors that increase risk of development of atrial fibrillation (AF) were 
mitral stenosis (MS), aortic stenosis (AS), dilated left atrium (LAD) and 
duration of rheumatic heart disease (RHD) and these factors more 
observed in females. Atrial fibrillation (AF) was common between mid-
twenty to mid-thirty. 
 
Atrial fibrillation increases the risk of hospitalization. The major indications 
were congestive heart failure (CHF) followed by thromboembolism 
(stroke/TIA account the majority) 
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Introduction 
Statement of the problem 
Rheumatic fever (RF) is a nonsuppurative complications of Group A 
streptococcal pharyngitis due to a delayed immune response. Rheumatic 
heart disease (RHD) is an established valvular lesion occurs decades after 
repeated episodes of rheumatic carditis that is pan-carditis in nature and 
follows streptococcal sore throat in two weeks-time. While potentially all 
valves can be affected, the mitral and the aortic valves are predominantly 
affected. The valves became regurgitant in the early period but with 
healing and fibrosis, valular stenosis develops decades later. Once there is 
established valvular affection other complications will follow. One of the 
major complications is atrial fibrillation (AF). (1-3) 
 
Although RF and RHD are rare in developed countries, they are still major 
public health problems among children and young adults in developing 
countries. The economic effects of the disability and premature death 
caused by these diseases are felt at both the individual and national levels 
through higher direct and indirect health-care costs.(4-6) 
 
Recently echocardiography based survey in some developing countries 
have estimated prevalence of RHD is 3-10 times compared to the previous 
estimates based on the clinical examination alone. (4, 7) 
 
Atrial fibrillation (AF) is the most common persistent cardiac arrhythmia. 
Generally non rheumatic atrial fibrillation is well studied in developed 
countries whereas rheumatic atrial fibrillation is not a big problem in the 
westerns. (7-9) But still the prevalence is higher in sub-Saharan Africa 
especially those with high incidence of RHD patients like Ethiopia. (10, 11)  
AF is associated with increased rates of death, stroke and other thrombo-
embolic events, heart failure and hospitalizations, degraded quality of life, 
reduced exercise capacity, and left ventricular (LV) 
dysfunction(12)Conditions associated with AF are also markers for global 
cardiovascular risk and/or cardiac damage rather than simply causative 
factors.(4, 7) 
Literature review 
 
Different studies have shown different results regarding the patterns of 
atrial fibrillation in chronic rheumatic vavlular heart disease patients. A 
study in Turkey, Ankara shows the highest frequency of AF in RHD 
occurs in those with mitral stenosis, mitral regurgitation, and tricuspid 
regurgitation in combination. AF, while occurring in 29% of patients with 
isolated mitral stenosis and in 16% with isolated mitral regurgitation, is 
an infrequent finding (1%) in patients with aortic valvular disease. Left 
atrial diameter by univariate analysis, and age and left atrial diameter 
by multivariate analysis have been shown to be the most important 
parameters to determine the occurrence of AF in patients with RHD(12) 
 
Most studies about AF in RHD are hospital based surveys and are not 
representative of the general prevalence in the community but this few 
hospital based publication shows that the rate of rheumatic AF still is 
higher especially in sub-Saharan Africa(Ethiopia). Generally reports 
from the developed countries very low compared with NonRheumatic 
AF. A report in Cameroon(13) shows that prevalence of AF is much 
higher compared with the developed countries because of combined 
risk factors(Rheumatic and NonRheumatic AF) and rheumatic account 
for 25.6%, also other reports in Uganda, cote d’ivoire, Ethiopia shows 
same thing. (14-17)  
 
Basically AF have different risk factors, this study focused Rheumatic 
AF and its pattern with respect to different valve lesions. Although 
clinical scoring system for prediction of high risk patient to developed 
atrial fibrillation in RHD is not well established. Inaccessibility of 
appropriate Echo and appropriate ECG makes it difficult to know the 
real prevalence and to stratify high risk features. A study in Ankara, 
Turkey shows rheumatic mitral stenosis have strong predictor, left atrial 
diameter and age are important confounders. AF, while occurring in 
29% of patients with isolated mitral stenosis and in 16% with isolated 
mitral regurgitation, is an infrequent finding (1%) in patients with aortic 
valvular disease done in 1996.(12) 
 
A prospective, hospital based clinical registry in Soweto study, South 
Africa among 344 case of RHD presenting to cardiology clinic in 2006/7 
calendar year AF was diagnosed in 34 cases(9.9%). The predominant 
valvular lesion (n = 204, 59%) was mitral regurgitation (MR), with 48 
(14%) and 43 (13%) cases, respectively, having combination lesions of 
aortic plus MR and mixed mitral VHD. Impaired systolic function was 
found in 28/204 cases (14%) of predominant MR and in 23/126 cases 
(18%) with predominant aortic regurgitation.(18) 
 
Another hospital base prospective pilot study, in Mulago hospital, 
Uganda among one hundred thirty patients AF prevalence is 13.9%. 
The majority of the patients presented with moderate-to-severe 
valvular disease. Pure mitral regurgitation was the commonest 
valvular disease (40.2%), followed by mitral regurgitation plus aortic 
regurgitation (29%). Mitral regurgitation plus aortic regurgitation plus 
mitral stenosis was found in 11% of patients. There was only one case 
involving the tricuspid valve.(15) 
 
Clinical records of 136 cardiac patients with atrial fibrillation (AF) 
followed in the cardiac clinic of the Black Lion Hospital, to study the risk 
of embolization in AF patients. RHD was found in 66.3% and 
responsible for embolization in 65.6%. Also a prospective study in 
Gondar also shows AF found in 22.8% of RHD cases Frequently 
encountered valve lesions were combined mitral regurgitation and 
stenosis seen in 29 (25.4%), followed by pure mitral stenosis in 25 
(21.9%) and mitral regurgitation in 21 (18.4%).(10, 11, 16) 
 
 
A retrospective study in USA focusing on the interrelation of factors 
contributing to the risk of AF in patients with mitral stenosis, we 
examined a cardiac catheterization database of a series of 314 
patients. Patients with AF were older, 53.4 +/- 6.1 years versus 51.7 +/- 
7.2 years (p = 0.03), and had a lower cardiac index of 2.3±0.6 L/min/m2 
versus 2.6±0.7 L/min/m2 (p = 0.0002), than patients in sinus rhythm at 
catheterization. The mitral valve area was significantly smaller in 
patients with AF than in patients in sinus rhythm, 1.2± 0.5 cm2 versus 
1.6±0.7 cm2 as was mitral valve index. The pressure-AF association 
with the highest statistical significance was seen with mean right atrial 
pressure, 10.6 +/- 4.9 mm Hg versus 7.6 +/- 3.8 mm Hg (odds ratio 
2.24; p < 0.0001). Other variables with significant positive associations 
by univariate analysis were pulmonary artery wedge pressure, 
pulmonary artery mean pressure, and pulmonary resistance. When 
stepwise logistic multiple regression analysis was performed, the 
results indicated that both severity of mitral stenosis and increased right 
atrial pressure were independently associated with AF in this 
population with mitral stenosis. After adjustment was performed for 
these variables, age was not independently associated with AF.(1, 5, 8, 
19) 
 
Justification of the study  
In Ethiopia, RHD is one of the common causes of cardiac illness among 
adolescents and young adults. However, there is scarcity of information on 
the pattern of AF among the RHD patients and associated co morbidities. 
On top AF, occur either as precipitant in heart failure or cause of stroke 
(especially stroke in young). There is scanty of publications, in Ethiopia, and 
all are local hospital-based studies. This clearly demonstrates the fact that, 
the prevalence of AF at community level is not yet known, which is 
attributed to the Lack of community-based studies.  A record review in 
Black Lion Hospital shows that RHD is responsible for 66.3% of AF. In 
another study in Gondar, 20 years ago, AF present among 22.8% of RHD 
patient, commonest arrhythmia and the third common precipitating factor for 
heart failure (drug discontinuation and infection). Therefore, this study is 
aimed at describing the socio-demographic and clinical predictors of AF 
among RHD patients. The information will give a baseline data for the 
setting and invites for the next steps of research and intervention to improve 
the health status of such patients.(10, 11, 16) 
 
 
 
 
 
 
 
 
 
 
 
 
Objectives of the study 
General objectives 
 To study the risk factors and predictors of atrial fibrillation in chronic 
rheumatic heart disease patients in cardiology follow up clinic in 
University of Gondar Hospital 
Specific objectives 
 To sort out associated risk factors for the development of atrial 
fibrillation and 
 To identify  the commonly associated types of valvular disease 
among atrial fibrillation  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials and Methods  
Study design and study area 
Institutional based retrospective patients chart record analysis was done to 
assess the risk factors and predictors associated with atrial fibrillation 
among patients with chronic rheumatic valvular heart disease in cardiology 
clinic of University of Gondar Hospital, North West Ethiopia  
A case-control study design selected with equal proportion on cases and 
controls (1:1) to study risk factors and predictors of atrial fibrillation (AF). 
Cases were all patients with atrial fibrillation and controls all patients without 
atrial fibrillation 
Study period 
From January 1st 2010- December 31st 2014 
Inclusion and exclusion criteria 
Inclusion criteria:  
Patients were included in the study if there age is ≥15 years and 
echocardiographic/clinical diagnosis of RHD with or without 
electrocardiographic (EKG) evidence of atrial fibrillation (AF) 
Exclusion criteria:  
Excluding patients if they were nonrheumatic AF or  
 AF with normal echocardiography or age less than 15 
 
 Study variables  
Dependent variables: 
 Atrial fibrillation(AF) (yes or no) 
Independent variables 
 Socio demographic factors  such as: age, sex, and address; 
 Clinical: duration of heart disease, total number of hospital 
admission, CHF,  and  thromboembolism; 
 Echocardiography parameters: left atrial dimension, mitral valve 
area, mitral stenosis, mitral regurgitation, aortic stenosis, aortic 
regurgitation, and tricuspid regurgitation; and 
 Treatment: Benzanthin penicillin 
Data collection and Statistical analysis 
  
Data was collected using structured questionnaires. Data analysis 
was done using using EPI 7.1.4. Continuous variables were 
calculated as mean ± SD (range). Odds ratio calculated for the 
exposure in both case and control groups using logistic regression 
analysis. 
Operational definition 
Atrial fibrillation defined as absent/or fibrillation P wave with/without 
irregular RR interval 
Chronic rheumatic valvular heart disease (CRVHD) defined 
according to World Heart Federation (WHF). (20) 
2012 WHF criteria for echocardiographic diagnosis of RHD 
Echocardiographic criteria for individuals aged ≤20 years 
Definite RHD (either A, B, C, or D): 
   A) Pathological MR and at least two morphological features of RHD of the MV 
   B) MS mean gradient ≥4 mmHg* 
   C) Pathological AR and at least two morphological features of RHD of the AV‡ 
   D) Borderline disease of both the AV and MV§ 
Borderline RHD (either A, B, or C): 
   A) At least two morphological features of RHD of the MV without pathological MR or MS 
   B) Pathological MR 
   C) Pathological AR 
Normal echocardiographic findings (all of A, B, C, and D): 
    A) MR that does not meet all four Doppler echocardiographic criteria (physiological MR) 
    B) AR that does not meet all four Doppler echocardiographic criteria (physiological AR) 
    C) An isolated morphological feature of RHD of the MV (for example, valvular 
thickening) without any associated pathological stenosis or regurgitation 
    D) Morphological feature of RHD of the AV (for example, valvular thickening) without any 
associated pathological stenosis or regurgitation 
Echocardiographic criteria for individuals aged >20 years 
Definite RHD (either A, B, C, or D): 
   A) Pathological MR and at least two morphological features of RHD of the MV 
   B) MS mean gradient ≥4 mmHg* 
   C) Pathological AR and at least two morphological features of RHD of the AV, only in 
individuals aged <35 years‡ 
     D) Pathological AR and at least two morphological features of RHD of the MV 
 
 
Ethical considerations 
The proposal was submitted and approved for analysis by IRB of the 
college of medicine and health science, University of Gondar (UoG), on 
june 2014. 
 
Results  
 
About 68 cases with complete medical record, data and fulfill the inclusion 
criteria were reviewed with fixed proportion between cases (AF) and 
controls (no AF) and analysed accordingly. The mean ages were 27.4±9.3 
with a range of 15-44 years and 26±10.9 (range 15-50) years in AF and no 
AF, respectively. Thirty (44.1%) patients in AF groups are in age range of 
25-34 years, whereas 35 (51.5%) of the patients in no AF groups are in 
younger age range of 15-24 years. In terms of sex distribution, male 
represent 15 (22.1%)  AF and 25 (36.8%) no AF. Their demographic and 
clinical characteristics and echocardiography characteristics are shown in 
Tables 1 and 2 
 
The mean duration of RHD among AF groups were 5.7±3.9 and NonAF 
3.9±2.9 years and only one patient in NonAF group had mechanical mitral 
valve. Total hospital admission is higher in AF groups and heart 
failure/cardiogenic shock being the commonest reason, followed by 
thromboembolism (stroke/TIA and peripheral ischemia). Other clinical risk 
factors for AF like hypertension, diabetes, CKD, HIV, dyslipidemia, COPD 
are not significant in both groups. (See Tables 1 and 2) 
 
Structural mitral valve disease commonly seen valve disease in both 
groups, echocardiographic evidence of Mitral stenosis and mitral 
regurgitation were found in 45(66.2%) and 43(63.2%) of patients with AF, 
23(33.8%) and 39(57.4%) no AF groups respectively. The mean areas for 
mitral valve were 17.8±12.4 mm2 and 24.3±14.4 in AF and NonAF groups, 
respectively. Left Atrial dimension (mm) (mean±SD) was 57.7±12.8 and 
43.9±9.1 in AF and no AF groups respectively. Left atrial dimension, degree 
of mitral stenosis and aortic stenosis were seen more in AF groups, where 
as aortic regurgitation are more seen in no AF groups. 
 
Medication use, 61(89.7%) in AF and 56(82.4%) in no AF groups were on 
benzanthin penicillin monthly IM injections. Aspirin, Warfarin, Beta-blockers 
and digoxin prescription were much higher in AF groups but enalapril was 
more in NonAF groups 12(17.6%) vs. 5(7.8%) and diuretics were 
comparable in both arms. Their medication prescription and outcome 
assessment see Table 3 below 
 
Table 1 Demographic and clinical characteristics of patients with chronic 
rheumatic valvular heart disease with AF (n=68) and no AF (n=68) 
 
 
 
 
Variable Frequency, percentage 
AF Non AF 
No of patients 68 68 
Age range 15-24 18(26.5%) 35(51.5%) 
25-34 30(44.1%) 15(22.1%) 
35-44 16(23.5%) 11(16.2%) 
Above 45 4(5.9%) 7(10.3%) 
Sex Male  15(22.1%) 25(36.8%) 
Female  53(77.9%) 43(63.2%) 
Area of residence  Urban  45(66.2%) 45(66.2%) 
Rural  23(33.8%) 23(33.8%) 
Total number of 
hospital 
admissions 
No admission 19(27.9%) 37(54.4%) 
1 25(36.8%) 25(36.8%)  
2 18(26.4%) 5(7.4%) 
3 or more 6(8.9%) 1(1.5%) 
Reason for 
hospital 
admission 
CHF 44(64.7%) 27(39.7%) 
Thromboembolism  6(8.8%) 3(4.4%) 
Hypertension  0 2(3%) 
HIV infection 
 
1(1.5%) 1(1.5%) 
Epilepsy 1(1.5%) 1(1.5%) 
CKD 0 1(1.5%) 
CHD/PDA  0 1(1.5%) 
Smoking   0 0 
Diabetes 0 0 
COPD or Dyslipidemia 0 0 
Table 2 Shows clinical and echocardiography characteristics of patients 
with chronic rheumatic valvular heart disease with AF(n=68) and no AF 
(n=68) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3 Echocardiographic characteristics and Medication prescription of 
patients with chronic rheumatic valvular heart disease with AF (n=68) and 
no AF(n=68) 
 
 
Variables Mean+/-SD 
AF(n=68) NO AF(n=68) 
Age (year) 27.4+/-9.3 26+/-10.9 
Heart Disease 
Duration ( years) 
5.7+/-3.9 3.9+/-2.9 
Left Atrial dimension 
(mm)  
57.7+/- 12.8 43.9+/-9.1 
MV area (mm2) 17.8+/- 12.4 24.3+/-14.4 
   
Variables Frequency, percentage 
AF(n=68) NO AF(n=68) 
Mitral regurgitation(MR) 43(63.2%) 39(57.4%) 
Aortic regurgitation(AR)  7(10.3%) 13(19.1%) 
Tricuspid regurgitation(TR)  27(39.7%) 21(30.3%) 
Pulmonary regurgitation(PR) 00 00 
Mitral stenosis(MS) 45(66.2%) 29(42.6%) 
Aortic stenosis(AS) 6(8.8%) 3(4.4%) 
Tricuspid stenosis(TS) 00 00 
Pulmonary stenosis(PS) 00 00 
Beta blockers 24(37.5%) 9(13.2%) 
Diuretics  60(93.8%) 55(80.9%) 
Digoxin 36(56.3%) 10(14.7%) 
Aspirin  31(45.6%) 2(3%) 
Warfarin  11(17.2%) 3(4.45%) 
Benzanthin penicillin 61(89.7%) 56(82.4%) 
Enalaprin  5(7.8%) 12(17.6%) 
Amiodarone  0 0 
Calcium channel blockers 0 0 
Stroke/TIA 6(8.8%) 2(3.0%) 
Peripheral embolization  00(0%) 1(1.5%) 
Open heart surgery   0 1(1.5%) 
Catheter ablation 0 0 
Table 4. Bivariate and multivariate logistic regression analysis of factors 
associated with atrial fibrillation, University of Gondar, Northwest Ethiopia 
 
*= Statistically significant at P<0.05 and **= P<0.01 
 
 
*= Statistically significant at P<0.05 and **= P<0.01 
 
 
 
 
Variables Atrial fibrillation OR with 95% CI P- 
value Yes No Crude(COR) Adjusted(AOR) 
Sex 
 
Male  15 25 0.49(0.23,1.03) 0.36(0.13,1.03)* 0.05* 
Female 53 43 1 1 
 
Mitral 
regurgitation(MR) 
Yes 43 39 1.28(0.64,2.55) 2.68(0.86,8.36) 0.09 
No  25 29 1 1 
 
Aortic 
regurgitation(AR)  
Yes  7 13 1 1  
No  61 55 0.49(0.18-1.3) 0.10(0.01,0.7)* 0.019* 
Tricuspid 
regurgitation(TR)  
Yes  27 21 1.47(0.73,2.99) 0.72(0.26,1.99) 0.53 
No  41 47 1 1  
Mitral 
stenosis(MS) 
Yes  45 29 2.63(1.31,5.27)* 4.22(3.99,4.78)* 0.04* 
No 23 39 1 1 
 
Aortic 
stenosis(AS) 
Yes 6 3 2.10(0.50,8.75) 20.65(1.84,232.1)*
* 
0.01** 
No  62 65 1 1 
 
Benzanthin 
penicillin  
Yes 61 56 1.87(0.67,5.08) 3.04(0.78,11.76) 0.11 
No  7 12 1 1 
 
Variables Atrial fibrillation  AOR Pvalue 
Yes  No 
Heart Disease 
Duration( years) 
5.7+/-3.9 3.9+/-2.9 1.23(1.01,1.50)* 0.039** 
Left Atrial dimension 
(mm)  
57.7+/- 12.8 43.9+/-9.1 1.15(1.08-1.22)** 0.00** 
MV area(mm2) 17.8+/- 12.4 24.3+/-14.4 1.0(0.94,1.07) 0.96 
 Table (continued). Bivariate and multivariate logistic regression analysis of 
factors associated with atrial fibrillation, University of Gondar, Northwest 
Ethiopia 
 
*= Statistically significant at P<0.05 and **= P<0.01 
 
 
 
 
 
 
 
 
 
 
 
  
Variables Atrial fibrillation(AF) OR with 95% CI P value 
Yes No COR AOR 
Stroke/TIA Yes 6 2 3.19(0.62,16.48)  0.96 
 No 62  66 1 1 
 
Peripheral 
embolization  
Yes 0 1 2.09(0.50,8.75)  0.96 
 No 68 67 1 1 
 
Congestive 
heart failure 
CHF) 
Yes 44 27 2.78(1.39,5.58)** 2.69(1.33-5.42) 0.0057** 
No 24 41   
 
Total 
number of 
admissions 
Yes 49 31 2.33(1.47,3.69)** 3.49(1.38,8.79) 0.008** 
no 19 37 1 1 
 
Discussion  
 
In this study mitral stenosis (MS), aortic stenosis (AS) and dilated left atrial 
chamber increases the risk of development of atrial fibrillation (AF) among 
RHD patients. A hospital review in Turkey/Ankara shows highest frequency 
of AF in RHD occurs in those with mitral stenosis (MS), mitral regurgitation 
MR), and tricuspid regurgitation (TR) in combination. AF, while occurring in 
29% of patients with isolated mitral stenosis and in 16% with isolated mitral 
regurgitation, is an infrequent finding (1%) in patients with aortic valvular 
disease. (12) A pilot study in Mulago Hospital showed that all patients with 
RHD presented with dilated atria (> 49 mm). (15) there are similarities 
between those studies LA size and MS increase risk of AF. 
 
Commonly associated valve lesions were mitral stenosis (MS) and aortic 
stenosis (AS) statistically significant. Others like mitral regurgitation (MR) 
and tricuspid regurgitation (TR) almost always functional due to pulmonary 
venous hypertension were increase risk but not statistically significant. 
Aortic regurgitation (AR) no association seen. The possible explanations 
why stenotic valve lesions increase the risk were because of the duration of 
the disease and subsequent remodeling cardiac structure for atrial 
fibrillation (AF) development. These finding also supported by other studies 
were. (12, 15)  
 
Another important finding was duration of rheumatic heart disease (RHD) 
increases the risk of development of atrial fibrillation (AF). There was no 
another study which compares this association previously. Female sex 
have higher rate of RHD and increased risk of development of AF a study in 
Cameroon(17), Turkey(12) and some sub-Saharan countries(13) showed 
increased rate of female patients with RHD and did not evaluate risk of 
development of AF among those patients. This is observed in this study too 
and the possible reasons were attributed to poor socioeconomic status, lack 
of women empowerment and financial dependency, lack of knowledge and 
awareness about health, and cultural beliefs.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 the distribution of commonly associated rheumatic valve lesions  in 
both AF and Non AF groups 
 
 
 
 
 
Majorities of our patients with atrial fibrillation (AF) fall under age range (25-
34) means between min-twenty and mid-thirty years of life, where as non 
AF RHD range of 15-24 years. This finding also supports the previously 
discussed finding about duration of RHD. (See fig 2),  
 
The study also revealed that, atrial fibrillation (AF) significantly increase the 
risk of hospitalization among RHD patients and the major reason identified 
was congestive heart failure ( with or without cardiogenic shock) and fewer 
cases of thromboembolic complication than expected but higher than the 
controls. This finding is in agreement with studies done in Ethiopia (11, 
16),USA (1, 19) and Soweto (18). This is an indication that the finding is 
scientifically sound. When patients develop atrial fibrillation(AF) the cardiac 
output decreased by more than 30% of the baseline and those patients with 
underlying RHD already have compromised output, so these combined 
effect can cause deterioration of cardiac function and increase risk of CHF 
and  thromboembolism.  
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Figure 2 characteristics of age distribution in AF 
 
 
 
 
 
 
 
 
 
 
 
 
0
5
10
15
20
25
30
35
15-24 25-34 35-44 >44
N
u
m
b
e
 r
 o
f 
p
at
ie
n
ts
 
Age Range(years) 
AF
No AF
Limitation and strength of the 
study 
Limitation of the study 
This study has some important limitations that should be kept in mind when 
interpreting the results. First, the case-control nature of the study design 
does not strongly correlate cause and effect relationships. This is single 
hospital base study, which limits the number of cases and controls. In some 
charts, absence of proper documentation has also resulted in insufficient 
data and increases the risks of bias and variables   including appropriate 
echocardiography parameters were incomplete, that makes difficult to have 
a comprehensive analysis of risk factors.  Furthermore, the study was 
based on documented chart review with the potential of selection bias and 
random error plus recall bias upon documentation.  
Strength of the study of the study 
Despite these limitations, a standardized questionnaire based data 
collection mechanism is developed for future related research activities. 
 
 
 
 
 
 
 
 
Conclusion  
The overall factors, which increase the risk of atrial fibrillation (AF) 
development, were mitral stenosis (MS), aortic stenosis (AS), dilated left 
atrium (LAD) and duration of rheumatic heart disease (RHD) and this 
factors more observed in females. Atrial fibrillation (AF) was common 
between mid-twenty to mid-thirty. 
 
Atrial fibrillation increases the risk of hospitalization. The major indications 
were congestive heart failure (CHF) followed by thromboembolism 
(stroke/TIA account the majority) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Recommendations  
For an inclusive nationwide concrete information on the topic. I recommend 
more research with different design in different part of country.  
 
Screening protocol and scoring system development:  
1. Duration of rheumatic heart disease: above or below 5.5 years  
2. Left atrial dimension(mm): above or below 57mm 
3. Severe aortic stenosis (AS): yes or no 
4. Severe mitral stenosis (MS): yes or no 
5. Female sex 
Incorporation of other important parameters: socioeconomic status, 
benzanthin penicillin prophylaxis, echocardiographic evidence (flow rate 
and pressure gradient across high risk valve) 
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Annex 1:  Questionnaires for investigating the Predictors 
among patients with chronic rheumatic valvular heart disease 
following at cardiology clinic of University of Gondar Hospital, North 
West Ethiopia 
1. Identification and epidemiologic data 
     1.1. Card no…………. 
     1.2. Age (year) ………. 
 1.3. Age range (years)  
   1.3.1. <15……   1.3.2. 15-24….. 1.3.3. 25-34……. 
   1.3.4. 35-44……. 1.3.5. >45……  
     1.3. Sex: M…..          F…… 
     1.4. Address: Urban…….. Rural…….    
2. Clinical data 
    2.1. Heart disease duration diagnosis (in year)…………………. 
    2.2. Duration of Atrial fibrillation (in year)………………… 
    2.3. Any valve surgery, If Yes (how many years since surgery)………….. 
    2.4. Other medical illness (yes/no) 
        2.4.1. Hypertension……         2.4.8. Congenital heart disease…………. 
        2.4.2. Diabetes……………     2.4.9. Ischemic heart disease……… 
        2.4.3. HIV infection………… 2.4.10. Kidney disease (CKD)………       
        2.4.4. Dyslipidemia…………   2.4.11. Smoking (in pack years)……….. 
        2.4.5. Sleep apnea (OSAHS)…………2.4.12. COPD………………..                                  
        2.4.6. Other tachyarrythmias………… 
       2.4.7. Waist circumference (in cm)    
     2.5. Number of hospital admission ……………………….. 
 
     2.6. Reason for hospital admission (if yes, indication)  
A. CHF…..  B. Shock …….. C. Thromboembolism…… 
3. Investigation 
3.1. ECG (Atrial fibrillation) (yes/no) ……………………. 
              3.1.1. Other finding specify………………… 
     3.2. Echocardiography 
             3.2.1. Stenotic lesion (yes/no) and if yes (mild, moderate, severe) 
                  A. MS…………B. AS……… C. PS………… D. TS………….. 
             3.2.2. Regurgitant lesion (yes/no) if yes (mild. Moderate, severe) 
                  A. MR…………B. AR…….…..C. TR………   D. PR…… 
             3.2.3. Valve area (in mm)  
  A.  MVA…………………         B. AVA……….…. 
             3.2.4. LA dimension (in mm)………… 
             3.2.5. Wall thickness (in mm)  
 A. Interventricular septum (IVS)……..   
 B.  Posterior wall thickness (PWT)……….. 
             3.2.6. Systolic function LVEF (in %) …………………. 
 3.2.7. Diastolic function (if yes, grade) 
  A. Mild …… B. Moderate……. C. Severe…….. 
4.   Medication prescription (if yes, which one) 
      4.1. Beta blocker……………       4.6. Diuretics………….. 
      4.2. Benzanthin penicillin……… 4.7. Digoxin………… 
      4.3. Aspirin………….                 4.8. Amiodarone………………….. 
      4.4. Warfarin……………….         4.9. Other medication specify…………. 
      4.5. Calcium channel blocker………    
5. Surgical interventions (if yes) 
      5.1. Catheter ablation …………. 
      5.2. Open surgery ………….. 
6. Any thromboembolic complication (if yes)………. 
      If yes specify……………………………. 
 
